Sorrento Announces Selection of T-VIVA-19 as Targeted Protein Vaccine Candidate for SARS-CoV-2
Sorrento Therapeutics, Inc. announced today that it has published a pre-print publication describing initial pre-clinical results from its COVID-19 vaccination program, which introduced a novel targeted protein vaccine against COVID-19, referred to as T-VIVA-19.
